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PMCA4 inhibitorIsoform 4 of the plasmamembrane calcium/calmodulin dependent ATPase (PMCA4) has recently emerged as an
important regulator of several key pathophysiological processes in the heart, such as contractility and hypertrophy.
However, directmonitoring of PMCA4 activity and assessment of calciumdynamics in its vicinity in cardiomyocytes
are difﬁcult due to the lack of molecular tools. In this study, we developed novel calcium ﬂuorescent indicators by
fusing the GCaMP2 calcium sensor to the N-terminus of PMCA4 to generate the PMCA4–GCaMP2 fusion molecule.
We also identiﬁed anovel speciﬁc inhibitor of PMCA4,whichmight be useful for studying the role of thismolecule in
cardiomyocytes and other cell types.
Using an adenoviral system we successfully expressed PMCA4–GCaMP2 in both neonatal and adult rat
cardiomyocytes. This fusion molecule was correctly targeted to the plasma membrane and co-localised with
caveolin-3. It could monitor signal oscillations in electrically stimulated cardiomyocytes. The PMCA4–GCaMP2
generated a higher signal amplitude and faster signal decay rate compared to amutant inactive PMCA4mutGCaMP2
fusion protein, in electrically stimulated neonatal and adult rat cardiomyocytes. A small molecule library screen
enabled us to identify a novel selective inhibitor for PMCA4, which we found to reduce signal amplitude of
PMCA4–GCaMP2 and prolong the time of signal decay (Tau) to a level comparable with the signal generated
by PMCA4mutGCaMP2. In addition, PMCA4–GCaMP2 but not the mutant form produced an enhanced signal in
response to β-adrenergic stimulation. Together, the PMCA4–GCaMP2 and PMCA4mutGCaMP2 demonstrate
calcium dynamics in the vicinity of the pump under active or inactive conditions, respectively.
In summary, the PMCA4–GCaMP2 together with the novel speciﬁc inhibitor provides newmeans with which to
monitor calcium dynamics in the vicinity of a calcium transporter in cardiomyocytes and may become a useful
tool to further study the biological functions of PMCA4. In addition, similar approaches could be useful for studying
the activity of other calcium transporters during excitation–contraction coupling in the heart.
© 2013 Elsevier Ltd. All rights reserved.1. Introduction
The plasma membrane calcium/calmodulin dependent ATPase
(PMCA) is a ubiquitous calcium transporting enzyme which mainly
functions to extrude intracellular calcium (reviewed in [1]). In non-
excitable cells PMCA is understood to play a major role in calcium
extrusion [2], however in excitable cells (such as cardiomyocytes),odulin dependent ATPase; NCX,
ATPase; nNOS, neuronal nitric
tor; GCaMP2, GFP-calmodulin-
rintricarboxylic acid.
iences, University ofManchester,
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4 161 2755669.
. Oceandy).
ghts reserved.its importance in respect to bulk calcium transport has traditionally
been assumed to be minor. Using serial pharmacological inhibitors,
several studies have shown that the majority of cytosolic calcium
removal is via the sarcoplasmic reticulum ATPase (SERCA) and sodium/
calcium exchanger (NCX) (reviewed in [3]). PMCA1 and PMCA4 are the
two isoforms expressed in the cardiomyocytes [4] and their high afﬁnity
for calcium has led to speculation that they may participate in, or ﬁne
tune, diastolic calciumextrusion [5,6]. Based on an alternative hypothesis,
our group and others have identiﬁed a signalling role for isoform 4 of the
PMCA (PMCA4). PMCA4 interacts with and modulates the activity of
other molecules, which have signiﬁcance in cardiac physiology. For
example, PMCA4 modulates cardiac contractility and hypertrophy
by regulation of neuronal nitric oxide synthase (nNOS) and calcineurin,
respectively [7–10]. Both nNOS and calcineurin are calcium-dependent
enzymes and it is therefore logical to speculate that PMCA4may be im-
portant in deﬁning calcium concentration within its vicinity and hence
alter the activity of its interacting partners.
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lating local calcium concentration [7,10,11], it is important to
develop a novel tool to assess calcium dynamics in the vicinity of
PMCA4. In this study we fused PMCA4 with a genetically encoded
calcium indicator (GECI) [12,13] and characterized its properties
in situ in cardiomyocytes. We used the GFP-based GECI (GCaMP2),
which exploits the calcium/calmodulin dependent rearrangement of
recombinant GFP that results in an increase in ﬂuorescence intensity
upon binding with calcium/calmodulin [14]. It has been shown in a
number of models that GCaMP2 ﬂuorescent intensity is a function of
calcium concentration [14]. It was also reported previously that using
transgenic mouse technology, expression of GCaMP2 in the heart can
be used to examine calcium transients in vivo [13]. The high brightness
and stability of GCaMP2 enable the measurement of the rapid
changes in Ca2+ transients in all regions of the beating mouse
heart and for prolonged pacing and mapping studies in isolated,
perfused hearts [13]. Here we used an adenoviral system to enable
the delivery of GCaMP2 in isolated/cultured cardiomyocytes and assess
the ability of this adenoviral-based GCaMP2 to detect rapid calcium
ﬂuctuations in isolated cardiomyocytes. We also generated adenoviruses
to enable expression of two fusion molecules: PMCA4–GCaMP2 and
PMCA4mutGCaMP2. In addition, through screening a medically optimised
chemical library we have identiﬁed a new and highly selective PMCA4
inhibitor, which was very useful in studying the fusion ﬂuorescent
molecules. Our analyses suggest that the indicators were able to
report calcium dynamics in the local vicinity of PMCA4 which was
dependent on PMCA4 activity.2. Methods
2.1. Adenovirus
Adenoviruses expressing the cytoplasmic GCaMP2 (cytoplasmic
calcium sensor) [13] were generated by cloning GCaMP2 (a generous
gift from J Nakai, Saitama, Japan) to the pAd/CMV/V5-DEST vector
(Invitrogen) using the Gateway system (Invitrogen) following the
manufacturer's instructions. To generate adenovirus expressing
GCaMP2 linked to PMCA4 or PMCA4mut, we cloned GCaMP2 cDNA to
the N terminal end of PMCA4 or PMCA4mut and then subcloned the
resulting construct to the pAd/CMV/V5-DEST vector as above.2.2. Isolation of adult and neonatal cardiomyocytes and western blot
analysis
Adult cardiomyocytes were isolated from 2 to 3-month old rats.
In brief, rats were sacriﬁced by cervical dislocation, the hearts were
rapidly removed and then perfused via the aorta with isolation solution
pH 7.34 (134 mM NaCl; 11 mM Glucose; 4 mM KCl; 1.2 mM MgSO4;
1.2 mM NaH2PO4; 10 mM HEPES) for 4 min followed by 9 min
perfusionwith a solution containing 0.6 mg/ml and 0.075 mg/ml of col-
lagenase type II (Worthington) and proteases type XIV (Sigma-Aldrich),
respectively. Hearts were then perfused with Tyrode solution containing
50 mM taurine pH 7.34 for 12 min. The ventricles were cut from the
heart and placed in Tyrode–taurine solution. The ventricles were
then cut in half and pipetted up and down through a Pasteur pipette
in 5 ml of Tyrode–taurine solution to release the cardiomyocytes.
The cardiomyocytes were then plated on laminin coated coverslips,
infected with adenovirus and cultured for 48 h using a previously
described protocol [15].
Neonatal rat cardiomyocytes (NRCM) were isolated from 1 to 3-day
old Sprague Dawley rat neonates using a protocol as described pre-
viously [16]. Western blot analyses using anti-GFP (Abcam) and
anti-GAPDH (Abcam) (loading control) were carried out as described
before [17].2.3. Immunoﬂuorescence
Neonatal or adult rat cardiomyocytes were plated on laminin coated
coverslips. Cells were washed twice with PBS and then ﬁxed by adding
0.5 ml 4% formaldehyde for 15 min. Fixed cells were washed three
times with PBS then permeabilised with 0.1% Triton X-100 for 15 min
and blocked with 10% horse serum in PBS for 30 min at room tempera-
ture. Cells were then probed with monoclonal mouse FITC conjugated
anti-GFP (Abcam) or monoclonal mouse anti-caveolin-3 antibodies
(BD) (1/100) diluted in 1% horse serum for 1.5 h at room temperature,
washed three times in PBS and then labelled with TR conjugated anti-
mouse (1/200) (Jackson Lab) diluted in 1% horse serum for 1.5 h in
the dark. The cells were then washed a further three times in PBS and
once in water. Coverslips were mounted onto slides using a Prolong
Antifade™ Kit (Molecular Probes) and cell staining was visualized
using a Leica SP5 confocal microscope.
2.4. Calcium transient recordings using GCaMP2, PMCA4-GCaMP2 and
PMCA4mutGCaMP2
NRCM or adult rat cardiomyocytes were infected with adenovirus
for the speciﬁc calcium sensor for 48 h. In order to measure calcium
transients the coverslips containing infected myocytes were placed in
a bath with a cover slip base. This bath was positioned on the stage of
an epiﬂuorescence adapted inverted Olympus IX70 microscope ﬁtted
with an Olympus America camera. The myocytes were perfused with
Tyrode solution and then ﬁeld stimulated by two silver wire electrodes
initiating an electrical current at a frequency of 1 Hz. Calcium oscilla-
tions during myocyte contraction were recorded at 33 °C. Excitation
was set at 485 nm using an ARC lamp (Cairn Inc), by means of a laser
spot applied to small areas of the cell. The ﬂuorescence emission at
525 nm was collected using a dichroic ﬁlter and a Cairn Integra
photomultiplier tube. The data were collected and analyzed using
Ionwizard software (Ionoptix Inc.). The calcium transients signal was
represented as a ratio of the post-stimulation ﬂuorescence, F, divided
by the mean pre-stimulation baseline ﬂuorescence, F0 for each cell.
The single exponential tau was calculated using the Ionwizard software
(Ionoptix Inc.) as the exponential decay time constant of the calcium
transients following the exponential ﬁtting of the calcium transients
decay slope and calculated as tau = 1/Kfall where Kfall = exponential
rate constant of the calcium decay. Caffeine experiments were carried
out by perfusing the cardiomyocytes with normal Tyrode solution
(TS). Then cells were rapidly perfused with 10 mM caffeine for 3 min
using an 8 channel local rapid perfusion system (MPER8 (Cairn research
LTD)) which was placed in close proximity to the cell to ensure rapid
application of caffeine. For 0Na/0Ca experiments the cellswere perfused
with Na+ and Ca2+-free Tyrode solution (0Na0Ca), in which all sodium
salts were replaced with lithium salts, for 60 s prior to caffeine applica-
tion. Indo-1 experiments were performed following methods described
elsewhere [7,17].
2.5. Microsomal preparation and coupled enzyme assay for PMCA4 activity
HEK293 cells were infected with the PMCA4 [7], PMCA4–GCaMP2,
PMCA4mutGCaMP2, GCaMP2, or LacZ adenovirus for 48 h. Microsomal
membrane preparations were carried out from the transfected cells as
follows: cells were washed three times with PBS and then harvested
in 5 ml harvest solution (1× PBS, 0.26% 2 mg/ml aprotinin, 0.11%
2 mg/ml leupeptin, 0.1% 0.1 M PMSF). Harvested cells were centrifuged
at 1000 ×g for 10 min at 4 °C. 3 ml hypotonic solution (10 mM
Tris–HCl, pH 7.5, 1 mM MgCl2, 0.5 mM EGTA, 2 mM DTT, 0.2% 2 mg/ml
aprotinin, and 0.05% 2 mg/ml leupeptin) was added to the cell pellet for
10 min on ice. Swelled cellswere homogenised in aDounce homogenizer
before addition of 3 ml homogenate solution (10 mM Tris–HCl, pH 7.5,
2 mM DTT, 0.38 M sucrose, 0.3 M KCl, 0.2% 2 mg/ml aprotinin, and
0.05% 2 mg/ml leupeptin); homogenization was completed to seal the
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Fig. 1. Adenoviral expression of GCaMP2 in isolated cardiomyocytes. (A) Neonatal and
adult rat cardiomyocytes were infectedwith adenovirus expressing GCaMP2 calcium sen-
sor (Ad-GCaMP2). Expression and localization of GCaMP2was detected using anti-GFP anti-
body. (B) Representative signal oscillations produced by the GCaMP2 sensor in neonatal and
adult rat cardiomyocytes following electrical stimulation at 1 Hz. (C) Effect of 100 nM
isoprenaline on calcium oscillations detected by GCaMP2 sensor in adult cardiomyocytes.
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remove the cellular debris. 60 μl 0.25 mM EDTA and 1.08 ml of 2.5 M
KCl were added to the supernatant and centrifuged at 100,000 ×g for
40 min at 4 °C. The resulting pelletwas re-suspended in 0.4 mlﬁnal solu-
tion (10 mM Tris–HCl, pH 7.5, 1 mM DTT, 0.19 M sucrose, 0.15 M KCl,
0.2% 2 mg/ml aprotinin, 0.05% 2 mg/ml leupeptin and 0.02 mM CaCl2).
The coupled enzyme assay was carried out as previously described [18].
2.6. Global intracellular calcium assay using GCaMP2 fusion proteins
To compare the basal ﬂuorescence signal intensity between PMCA4–
GCaMP2 and PMCA4mutGCaMP2 we used a modiﬁcation of the method
described in [19]. Brieﬂy, NRCM were plated in black walled glass
bottom 96 well plates and infected with PMCA4–GCaMP2 or
PMCA4mutGCaMP2 for 48 h. On the day of the assay, the medium
was replaced by 100 μl of fresh Hanks' balanced salt solution (HBSS)-
bovine serum albumin (BSA)-probenecid solution (HBSS, 1%w/v BSA
and 2.5 mM probenecid) in which NRCM were incubated for 30 min
at 37 °C. Cells were then washed with 100 μl of HBSS-BSA-probenecid
and ﬁnally maintained in 80 μl of fresh HBSS-BSA-probenecid contain-
ing 1.26 mM calcium chloride. Baseline ﬂuorescence (F) was measured
for three minutes with ﬁlters for excitation at 485 nm and for emission
at 538 nmusing a BMG FLUOstar Omega plate reader. Following baseline
ﬂuorescencemeasurement, 14 μl of Fmin solution (HBSS-BSA probenecid,
pH 7.45, 100 μM ionomycin, 10 μM Thapsigargin and 20 mM EGTA,
pH 8.0) was added to each well to deplete the calcium from the
cells and leave only the autoﬂuorescence which was measured for
120 min (Fmin). Finally, 16 μl of Fmax (250 mM calcium chloride in
HBSS-BSA probenecid) solution was added to saturate the cells with cal-
cium and ﬂuorescence was measured for another ﬁveminutes (Fmax). To
test the effect of various calcium concentrations on the ﬂuorescent inten-
sity of the sensors, we varied the calcium chloride concentration in the
Fmax solution to produce corresponding free calcium concentration in
the medium ranging from 100 nM to 10 mM as calculated using an on-
line software tool based on the Fabiato formula (http://www.stanford.
edu/~cpatton/CaEGTA-NIST.htm).
2.7. Identiﬁcation of a novel PMCA4 inhibitor
Using a modiﬁed coupled enzyme ATPase assay for PMCA4 activity
[18], we screened a library of 1280 medically optimised drug-like
molecules (LOPAC1280) (Sigma-Aldrich) against PMCA4 activity in
membrane microsomes derived from HEK293 cells overexpressing
PMCA4 protein as described in detail above under Section 2.5. The
ﬁrst round of screeningwas used to select compoundswith an inhibitory
effect of more than 50% at 10 μM concentration. These preselected com-
pounds underwent a counter assay to identify whether they exhibited
an effect on the coupled enzyme assay components where 10 mM
adenosine 5′-diphosphate sodium salt (ADP) was used to start up the
coupled enzyme reaction instead of microsomes. Identiﬁed inhibitors
which had no effect on the coupled enzyme assay components were
then conﬁrmed with a fresh solid bought from Sigma-Aldrich and
dose response curves for these compounds were carried out. To test
the speciﬁcity of the most potent identiﬁed inhibitor for PMCA4 over
other ATPases expressed in the heart, we used membrane microsomes
derived from HEK293 cells overexpressing PMCA4, SERCA2a or PMCA1
[7,17] and puriﬁed Na+/K+ ATPase (Sigma-Aldrich). The inhibitory effect
was tested over a range of concentrations in each microsome using the
modiﬁed coupled enzyme assay [18].
2.8. Statistical analysis
Data are expressed as mean ± SEM. Student's t test or one way
ANOVA followed by post-hoc multiple comparison were used where
appropriate. The probability level for statistical signiﬁcance was set at
p b 0.05.3. Results
3.1. Adenoviral-based expression of GCaMP2 in neonatal and adult rat
cardiomyocytes
Wegenerated adenovirus expressing the GCaMP2molecule driven by
a cytomegalovirus (CMV) promoter. The virus successfully induced the
expression of GCaMP2 in cultured neonatal rat cardiomyocytes and
adult rat cardiomyocytes. Using confocal immunoﬂuorescence analysis
we detected that GCaMP2 was mainly localised in the cytoplasmic com-
partment of both types of cells (Fig. 1A). Under electrical stimulation
(1Hz) both neonatal and adult cardiomyocytes overexpressing GCaMP2
showed consistent signal oscillations (Fig. 1B). Furthermore, stimulation
of adult cardiomyocytes with 100 nM isoprenaline resulted in a signiﬁ-
cant enhancement in the GCaMP2 signal (Fig. 1C). These results showed
that our GCaMP2 expressing adenovirus was able to monitor calcium
oscillations in cultured neonatal and adult rat cardiomyocytes during
the excitation–contraction coupling process.3.2. Generation of PMCA4–GCaMP2 fusion proteins
To generate a PMCA4 based GCaMP2 indicator, we cloned GCaMP2
directly to the N-terminus of full-length PMCA4 (PMCA4–GCaMP2).
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carries an Asp672Glu amino acid substitution, thereby reducing the
ATPase activity by 90% [20] (we named the recombinant molecule asB
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61T.M.A. Mohamed et al. / Journal of Molecular and Cellular Cardiology 63 (2013) 57–68promoter-driven. To determine the localization of these recombinant
proteins in transduced cardiomyocytes we used confocal immuno-
ﬂuorescence analysis using anti-GFP antibodies. Results presented
in Fig. 2B&C showed the expected sub-cellular localization of both mole-
cules, i.e. in the plasma membrane. We performedWestern blot analysis
to ascertainwhether introduction of the Asp672Glumutation had affected
protein expression levels (Fig. 2D). Quantitative band density analysis
indicated that the level of protein expression was comparable between
PMCA4–GCaMP2, PMCA4mutGCaMP2 and GCaMP2 sensors (Fig. 2E).
To assess whether addition of GCaMP2 to the PMCA4 affected its
enzymatic activity we conducted an in vitro ATPase assay using a
coupled enzyme assay as described previously [18]. As shown in Fig. 2F
therewere no signiﬁcant effects of GCaMP2 addition on the ATPase activ-
ity of PMCA4. As expected, the PMCA4mutGCaMP2 showed signiﬁcantly
lower ATPase activity which was comparable to levels shown by the
negative controls (cells expressing cytoplasmic GCaMP2 or LacZ).
It was also important to evaluate whether the introduction of
the Asp672Glu mutation in the PMCA4 subunit affected the basal andmaximum ﬂuorescence signal intensities of the GCaMP2 subunit. To
address this question we conducted experiments to assess the basal
ﬂuorescence (F) in NRCM expressing either PMCA4–GCaMP2 or
PMCA4mutGCaMP2 protein. We then added Fmin solution (Ionomycin to
release the calcium from the stores and make the membrane permeable
to calcium, thapsigargin to block the SR calcium reuptake and EGTA to
chelate the calcium from the cells) to deplete the intracellular calcium
from the cells and record only the ﬂuorescence of the Ca2+-free fusion
proteins (Fmin) in the cells. This determination is possible because
the cellular autoﬂuroescence independent of the fusion proteins
was negligible (see LacZ controls). This was followed by addition
of Fmax solution containing 250 mM calcium chloride (Fig. 2G–H)
or Fmax solution containing variable calcium chloride concentrations
in the presence of ionomycin/thapsigargin (from the Fmin solution) to
introduce the desired free calcium levels (100 nM–10 mM; Supplemen-
tary Fig. 1). As shown in Fig. 2G–H and Supplementary Fig. 1, PMCA4–
GCaMP2 and PMCA4mutGCaMP2 fusion proteins showed similar
ﬂuorescence intensity under different conditions, suggesting that the
62 T.M.A. Mohamed et al. / Journal of Molecular and Cellular Cardiology 63 (2013) 57–68introduction of the pointmutation did not alter theﬂuorescence intensity
of the sensor.3.3. PMCA4–GCaMP2 and PMCA4mutGCaMP2 are localised in caveolae
We and others have suggested that in cardiomyocytes PMCA4
is localised in caveolae [21,22]. To analyse whether the recombi-
nant PMCA4–GCaMP2 and PMCA4mutGCaMP2 were also targeted
to the same sub-cellular compartment we conducted confocal
immunoﬂorescence imaging using anti-GFP antibodies as well as
anti-Cav3 antibodies. Fig. 3A&B clearly show the co-localisation of
PMCA4–GCaMP2 and PMCA4mutGCaMP2 with caveolin-3 (marker for
caveolae) in adult rat cardiomyocytes. Taken together, the data sug-
gested that our novel PMCA based GCaMP2 indicatorwas enzymatically
active and correctly targeted to the caveolae of isolated cardiomyocytes.3.4. PMCA4–GCaMP2 exhibited stronger calcium oscillation signals
compared to PMCA4mutGCaMP2
To assess the calcium oscillations detected by PMCA4–GCaMP2 and
PMCA4mutGCaMP2 during excitation–contraction coupling, we used
neonatal rat cardiomyocytes overexpressing these fusion proteins and
electrically stimulated them at 1 Hz. The results of these experiments
showed that the signal amplitude produced by PMCA4mutGCaMP2
comprised only 50% of that generated by PMCA4–GCaMP2 (Fig. 4A&B).
Furthermore, analysis of the rate of signal decay conﬁrmed that the active
PMCA4 exhibited a signiﬁcantly faster decay rate compared to the PMCA4
mutant fusion protein (Fig. 4C). Since PMCA4mutGCaMP2 displayed
almost negligible enzymatic activity (Fig. 2F) the signal produced by
thismolecule likely reﬂected calciumchanges in its local vicinity indepen-
dent of PMCA4 activity. The difference in the signal amplitude and decay
rate between the mutant and non-mutant molecule might be caused by
the combination of PMCA4 activity and the change in local calcium
concentration.0
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isolated neonatal rat cardiomyocytes following electrical stimulation at 1 Hz. Analysis of (B) sig
higher signal amplitude and faster decay rate compared to PMCA4mutGCaMP2 (n = 12–14 cel3.5. PMCA4–GCaMP2 fusion protein can detect PMCA4 involvement in cal-
cium extrusion at the plasma membrane
Next we conducted experiments to override the sarcoplasmic
reticulum (SR) ﬁlling by stimulation with 10 mM caffeine. This will
open the ryanodine receptors (RYR), which in turn will elevate the
cytoplasmic calcium. In this situation the only mechanism for calcium
removal will be the plasma membrane calcium extrusion systems,
mainly mediated by the sodium calcium exchanger (NCX) and PMCA.
The results of these experiments showed that the calcium signal pro-
duced by PMCA4mutGCaMP2 was 80% lower in amplitude compared
to the other two sensors (Fig. 5A&B). However, the calcium signal de-
tected by the PMCA4–GCaMP2 protein was similar to that detected by
the cytoplasmic GCaMP2 (Fig. 5A). Whilst we would expect a large
increase in the signal amplitude detected by PMCA4–GCaMP2
under these conditions due to the exclusive removal of intracellular
calcium through the plasma membrane systems, for the signal to
rise to the level detected by cytoplasmic GCaMP2 was not expected.
A likely explanation for this is saturation of the GCaMP2 sensor with
high levels of calcium following caffeine application [3]. It was previously
reported that the GCaMP2 sensor has the advantage of a low Kd value
(~150 nM) which enables the detection of relatively small changes in
calcium, such as those occurring in cardiomyocytes under physiological
conditions and during excitation contraction coupling; however, its
detection ability for changes in calcium concentration was limited
to ~1 μMfree calciumatwhich point the sensor signal becomes saturated
[14,23,24].
We conducted further experiments in the presence of an external
solution of 0Na+/0Ca2+ to inhibit NCX activity and force the cell to
extrude calcium only through PMCAs. As shown in Fig. 5C the rate of
calcium decay detected by PMCA4–GCaMP2 was faster compared to
that detected by cytoplasmic GCaMP2. Interestingly, PMCA4mutGCaMP2
showed a lower amplitude and slower signal decay rate compared to
PMCA4–GCaMP2 (Fig. 5D). The calcium decay rate as indicated by the
time to 50% decay to baseline was signiﬁcantly faster for the ﬂuorescent
signal recorded by PMCA4–GCaMP2 sensor compared to the other0
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protein was an active molecule, in particular if other means of calcium
extrusion were inhibited.
3.6. Identiﬁcation of a novel PMCA4 inhibitor
To further analyse the properties of the PMCA4–GCaMP2 molecule,
experiments using a speciﬁc PMCA4 inhibitor were required. Since
a speciﬁc and potent inhibitor of PMCA4 was not available [11] we
screened a library of medically optimised drug-like molecules to identify
novel PMCA4 inhibitors using a modiﬁed colorimetric ATPase assay [18].
We successfully identiﬁed eleven compounds that inhibited PMCA4
activity with an IC50 ranging from 0.1 μM to 6 μM (Supplementary
Figs. 1&2). The compound with the highest inhibitory effect was
aurintricarboxylic acid (ATA), a polyaromatic carboxylic acid derivative.
In vitro, the effect of ATAwas dose-dependent and speciﬁc. At a concen-
tration of 150 nM ATA inhibited PMCA4 activity by 50% and blocked
almost all of the PMCA4 activity at a concentration of 1 μM (Fig. 6A&B).
We then tested the speciﬁcity of ATA against other major ATPases
(SERCA2a and Na+/K+ ATPase) and the other PMCA isoform expressedin the heart (PMCA1) using the same coupled enzyme assay used in the
screening [18]. ATA did not inhibit the Na+/K+ ATPase, which is a related
P-type ATPase and only produced aminor effect on the second isoform of
PMCA expressed in the heart (PMCA1) as well as SERCA2a (Fig. 6B). Fur-
thermore, ATA at a dose as high as 10 μMdid not alter the global calcium
transient as recorded in adult cardiomyocytes using the ratio-metric
dye Indo-1 (Fig. 6C–E), an aggregate measure of the activities of calcium
transporters including SERCA, the Ryanodine receptor and the
Na+/Ca2+ exchanger. This is consistent with the idea that PMCA4 is
not involved in the regulation of bulk contractile calcium [3,17].
3.7. Effects of PMCA4 inhibition on the PMCA4–GCaMP2 fusion proteins
To ensure that ATA did not directly affect the ﬂuorescent intensity of
the GCaMP2 sensor we analyzed ﬂuorescent signals produced by NRCM
expressing cytoplasmic GCaMP2 in the presence of 10 μM ATA. As
shown in Fig. 7A ATA treatment did not alter the signal amplitude nor
decay rate of the cytoplasmic GCaMP2 sensor. We then performed
experiments to investigate the effect of PMCA4 inhibition on the ﬂuores-
cent signals produced by the PMCA4–GCaMP2 and PMCA4mutGCaMP2
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signal amplitude by over 45% and prolonged the time of signal decay
(Tau) of the PMCA4–GCaMP2 molecule to a comparable level to
the signal generated by PMCA4mutGCaMP2. In contrast, signal ampli-
tude as well as signal decay produced by the PMCA4mutGCaMP2
remained unaffected following ATA treatment (Fig. 7B&C). In addition,
perfusion of 10 μM ATA for 5 min prior to caffeine application did not
change the caffeine-induced signal of the cytoplasmic GCaMP2 and
PMCA4mutGCaMP2. In contrast, ATA signiﬁcantly reduced the caffeine-
induced signal amplitude of the PMCA4–GCaMP2 to the level comparable
to that produced by the PMCA4mutGCaMP2 (Fig. 7D). Together, our data
conﬁrms that the signal produced by the PMCA4mutGCAMP2 indicates
local calcium levels independent of the PMCA4 activity. The difference
in the amplitude between the two sensors may be attributable to the
activity of PMCA4.3.8. PMCA4 is highly activated following β-adrenergic signalling in adult
cardiomyocytes
It was previously reported that PMCA4 is also activated by protein
kinase A andC (PKA, PKC) dependent processes [25]. PKA phosphorylates
PMCA4 at a serine residue which is located downstream of the
calmodulin binding domain, thus this activation may be due to the
modulation of the autoinhibitory domain [26]. Protein kinase A is a
cAMP-dependent enzyme and is activated by β-adrenergic stimulation
[27]. We therefore tested whether PMCA4–GCaMP2 was activated
following β-adrenergic stimulation. To address this question we
conducted experiments on adult rat cardiomyocytes overexpressing
either PMCA4–GCaMP2 or PMCA4mutGCaMP2. These cells wereelectrically stimulated at 1 Hz and the calcium oscillationswere recorded
for each cell before and after stimulation with 100 nM isoprotere-
nol (Fig. 8A–B). The results of these experiments showed that
PMCA4–GCaMP2 fusion protein detected a twofold elevation in the cal-
cium oscillation amplitude and a signiﬁcantly faster decay rate.
However, no increase in signal amplitude or decay rate was detect-
ed by PMCA4mutGCaMP2 (Fig. 8C–D). These results showed that
PMCA4–GCaMP2 but not PMCA4mutGCaMP2 was activated following
β-adrenergic stimulation in adult cardiomyocytes.4. Discussion
In this study we have generated novel fusion proteins PMCA4–
GCaMP2 and PMCA4mutGCaMP2 that can be efﬁciently delivered to
isolated/cultured cardiomyocytes by using an adenoviral system.
Both molecules are localised in the caveolae, which is in agreement
with previous reports on sub-cellular localization of PMCA4 [22].
The key ﬁndings from the present study are: i) Both PMCA4–GCaMP2
and PMCA4mutGCaMP2 report Ca2+ transients; however, the signal
amplitude of the mutant molecules was 50% less than the wild type
one. Given that the enzymatic activity of the mutant protein was
almost negligible, the signal reported by the PMCA4mutGCaMP2 might
represent local calcium ﬂuctuation in the vicinity of the molecule in-
dependent of the pump activity, whereas the signal reported by the
PMCA4–GCaMP2 might be caused by the combination of PMCA4
activity and the change in local calcium. ii) Using a compound library
screen we have identiﬁed aurintricarboxylic acid (ATA) as a novel
speciﬁc PMCA4 inhibitor. iii) Inhibition of PMCA4 activity by ATA
modiﬁed signal amplitude and decay rate of PMCA4–GCaMP2 to a
65T.M.A. Mohamed et al. / Journal of Molecular and Cellular Cardiology 63 (2013) 57–68level similar with that of PMCA4mutGCaMP2. This implies that the
calcium pumping activity of PMCA4 might change the calcium ﬂux
in and around the pump.
One may argue that the lower signal produced by PMCA4mutGCaMP2
might be caused by a direct effect of the genetic mutation within PMCA4Change in amplitude
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cent intensity, suggesting that the GCaMP2 subunit in both fusion mol-
ecules displayed similar efﬁciency in detecting calcium. Therefore, the
difference in the signals produced by PMCA4–GCaMP2 and
PMCA4mutGCaMP2 following electrical stimulation or after caffeine ap-
plication was likely due to the difference of calcium levels around the
pump, which might be caused by the activity of PMCA4. This has been
further conﬁrmed by ourﬁnding that treatmentwith a novel PMCA4 in-
hibitor (ATA) reduced the signal amplitude and prolonged signal decay
produced by the PMCA4–GCaMP2 to the level similar with those pro-
duced by the PMCA4mutGCaMP2.
GCaMP2 is the latest generation of genetically encoded calcium indi-
cators (GECI) developed by J Nakai and colleagues [13,28] based on the
principle of circular permutation of ﬂuorescent proteins. The GCaMP2
structure comprises of the 13-residue peptide of the Ca2+ –calmodulin
binding domain of theMLC kinase (M13), which is inserted upstreamof
the C-terminal fragment of EGFP. The N-terminal EGFP fragment with
calmodulin is linked downstream of the above structure. Under basal
conditions this recombinant protein produces a low ﬂuorescent signal
since the C-terminal fragment of EGFP precedes the N-terminal frag-
ment. Binding with calcium will alter the conformation of GCaMP2
resulting in an increased ﬂuorescent signal [14].
GCaMP2 has been used previously for calcium imaging in various
models. Tallini et al. generated transgenic mice expressing GCaMP2 in
the heart, which enabled the measurement of myocyte Ca2+ transientsin vivo in all regions of the beating mouse heart [13]. In another study,
Lee et al. linked GCaMP2 with the α1 and α2 subunits of the Na+/K+
ATPase pump and overexpressed these in astrocytes. These sensors
were able to deﬁne a different subsarcolemmal calcium environment
related to each subunit [12]. More recently, GCaMP2was cloned to sub-
cellular targeting proteins to target the GCaMP2 to certain sub-cellular
localisations; an approach which proved successful in detecting sub-
cellular local calcium. For example, the Lck-GCaMP2 was able to detect
a sub-membrane calcium microdomain in neuronal cells [29], and the
mito-GCaMP2 has been developed for mitochondrial calcium imaging
[30]. Unlike other GCaMP2 sensors which were cloned to non-calcium-
regulating proteins, the PMCA4–GCaMP2 was the ﬁrst trial to fuse this
calcium sensor to a calcium pump.
Experiments using a speciﬁc inhibitor were needed to further
conﬁrm the ﬁndings. However, prior to this study there was no
known small molecule which acts as a speciﬁc inhibitor of PMCA4
activity. Inhibitors used in previous studies have either been general
inhibitors of the ATPase family such as lanthanum, vanadate and eosin
[31–37], or general calmodulin antagonists such as calmidazolium
[38]. Currently, carboxyeosin is the only available non-speciﬁc
pharmacological inhibitor for PMCA [39]. However, carboxyeosin
is a ﬂuorescent compound and would interfere with the GCaMP2
signal. We therefore performed inhibitor screening and obtained
a key result, i.e. the identiﬁcation of aurintricarboxylic acid (ATA)
as a potent PMCA4 inhibitor. ATA completely inhibited PMCA4
activity at a very low concentration (1 μM). At higher concentra-
tions (up to 100 μM) ATA has been reported to have several effects
on different cell types. For example, ATA has been described as an
anti-viral [40–45] and anti-apoptotic agent [51–53]. It also inhibits
several types of nucleases (DNAse I, RNAse A, SI nuclease, exonu-
clease) [46–48]. In the present study we used ATA at a very low
concentration and instantly detected the acute effects on the cells
using a PMCA4-based ﬂuorescent sensor. Therefore, the response
detected by the GCaMP2 fusion molecules was very likely due to
ATA action on PMCA4.
The PMCA4–GCaMP2 fusion protein may be very useful in further
understanding the signalling interplay between PMCA4 and its
interacting partners. Previously, we have described a physical interac-
tion between PMCA4 and other signallingmolecules in cardiomyocytes,
notably nNOS, α1-syntrophin, calcineurin and RASSF1A [8,49–51]. It is
known that overexpression of PMCA4 reduced the activity of its
interacting partners, for example nNOS and calcineurin [7,8,49]. How-
ever, it is not known whether local calcium dynamics around PMCA4
are altered in the situation of excess or depleted expression of its
interacting partners. PMCA4–GCaMP2 and PMCA4mutGCaMP2 can be
used as novel tools to examine local calcium changes under these
circumstances, in situ, which could offer insights into the role of these
interactions during a number of cardiac disease processes.
The discovery of a speciﬁc pharmacological inhibitor for PMCA4
could be extremely useful, not only as a tool in the study of the pump's
actions in the heart, but also in a number of other cell types and disease
processes. Our studies in mice lacking PMCA4 [37] have found male
mice to be infertile due to a defect in sperm motility, but otherwise
males and females were both completely healthy under physiological
conditions with a normal lifespan. Our ﬁndings were later conﬁrmed
by Okunade and colleagues who generated a similar PMCA4 knockout
mouse model [52]. In addition a very recent GWAS study showed the
PMCA4 gene to be associated with resistance to infection by malaria
plasmodium in humans [53]. Therefore, our discovery that ATA is a spe-
ciﬁc inhibitor for PMCA4 could have further potential applications in the
ﬁelds of contraception and anti-malaria treatment.
5. Conclusion
In this study we generated and analyzed the properties of two
novel PMCA4 based calcium indicators, PMCA4–GCaMP2 and
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67T.M.A. Mohamed et al. / Journal of Molecular and Cellular Cardiology 63 (2013) 57–68PMCA4mutGCaMP2. Together, PMCA4–GCaMP2 and PMCA4mutGCaMP2
can be used tomonitor calcium dynamics around these fusion proteins.
Those fusion molecules may also be useful in testing the efﬁcacy of
small molecules that can modulate PMCA4 function. In addition, using
a similar approach, the GCaMP2 sensor could be useful for studying
other calcium transporters such as SERCA, NCX, TRPCs and IP3 receptors
during excitation–contraction coupling in cardiomyocytes. The second
aspect of this study, our discovery of a speciﬁc PMCA4 inhibitor will
enable further investigations into the precise role of PMCA4 in other
cell types, with potential implications for the ﬁelds of fertility and
malaria.
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